• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Brain Ischemia - Pipeline Review, H2 2012 Product Image

Brain Ischemia - Pipeline Review, H2 2012

  • Published: November 2012
  • 44 pages
  • Global Markets Direct

Brain Ischemia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Brain Ischemia - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Brain Ischemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Brain Ischemia. Brain Ischemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Brain Ischemia.
- A review of the Brain Ischemia products under development by companies and universities/research institutes based on information READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Brain Ischemia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Brain Ischemia 7
Brain Ischemia Therapeutics under Development by Companies 9
Brain Ischemia Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Brain Ischemia Therapeutics – Products under Development by Companies 14
Brain Ischemia Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Brain Ischemia Therapeutics Development 16
Sylentis 16
Merck KGaA 17
KeyNeurotek Pharmaceuticals AG 18
AGY Therapeutics, Inc. 19
NeuroNascent, Inc. 20
Brain Ischemia – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
IPC-1755 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Clopidogrel + Aspirin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
nimodipine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Drug For Cerebral Ischemia - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
fingolimod hydrochloride - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
MDF-005 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
AGS Neural Stem Cells - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
AS-605240 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 35
NR2B Program For Neuronal Protection - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Drug Targeting AGY-221 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Drug targeting AGY-220 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Drug Targeting AGY-218 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Brain Ischemia Therapeutics – Drug Profile Updates 40
Brain Ischemia Therapeutics - Dormant Products 41
Brain Ischemia – Product Development Milestones 42
Featured News & Press Releases 42
Nov 03, 2010: SurModics And Edge Therapeutics Collaborate On Development Of NimoGel 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
Number of Products Under Development for Brain Ischemia, H2 2012 7
Products under Development for Brain Ischemia – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
Sylentis, H2 2012 16
Merck KGaA, H2 2012 17
KeyNeurotek Pharmaceuticals AG, H2 2012 18
AGY Therapeutics, Inc., H2 2012 19
NeuroNascent, Inc., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Brain Ischemia Therapeutics – Drug Profile Updates 40
Brain Ischemia Therapeutics – Dormant Products 41

List of Figures
Number of Products under Development for Brain Ischemia, H2 2012 7
Products under Development for Brain Ischemia – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Discovery and Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos